Comments on final report of the AIO colorectal cancer group study: Fluorouracil/oxaliplatin versus capecitabine/oxaliplatin

被引：1

作者：

Buechele, Thomas ^{[1
]}

机构：

[1] F Hoffmann La Roche & Co Ltd, Div Pharmaceut, Pharma Business Oncol, Basel, Switzerland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 31期

关键词：

D O I：

10.1200/JCO.2007.13.7158

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：5041 / 5042

页数：4

共 5 条

[1]

BENNOUNA J, 2007, 2007 GASTR CANC S PR

[2]

CASSIDY J, 2007, J CLIN ONCOL S, V25, pS18

[3] Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 [J].

Giantonio, Bruce J. ;

Catalano, Paul J. ;

Meropol, Neal J. ;

O'Dwyer, Peter J. ;

Mitchell, Edith P. ;

Alberts, Steven R. ;

Schwartz, Michael A. ;

Benson, Al B., III .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1539-1544

[4] Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO colorectal study group [J].

Porschen, Rainer ;

Arkenau, Hendrik-Tobias ;

Kubicka, Stephan ;

Greil, Richard ;

Seufferlein, Thomas ;

Freier, Werner ;

Kretzschmar, Albrecht ;

Graeven, Ullrich ;

Grothey, Axel ;

Hinke, Axel ;

Schmiegel, Wolff ;

Schmoll, Hans-Joachim .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) :4217-4223

[5]

Saltz L, 2007, J CLIN ONCOL, V25, p18S

← 1 →